Reducing GBA2 activity ameliorates neuropathology in niemann-pick type C mice

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Marques, André R A ^a   Aten, Jan ^a   Ottenhoff, Roelof ^a   Van Roomen, Cindy P A A ^a   Moro, Daniela Herrera ^a   Claessen, Nike ^a   Veloz, María Fernanda Vinueza ^b   Zhou, Kuikui ^b   Lin, Zhanmin ^b   Mirzaian, Mina ^a   Boot, Rolf G ^a   De Zeeuw, Chris I ^b,c   Overkleeft, Herman S ^d   Yildiz, Yildiz ^e   Aerts, Johannes M F G ^a,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GANGLIOSIDE; GLUCOCEREBROSIDASE 2; GLUCOSYLCERAMIDASE; IMINOSUGAR; UNCLASSIFIED DRUG; BETA GLUCOSIDASE; BETA-GLUCOSIDASE 2, MOUSE; GLUCOSYLCERAMIDE; NPC1 PROTEIN, MOUSE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; INHIBITION KINETICS; LIFE EXTENSION; LIPID ANALYSIS; LYSOSOME; MALE; MOTOR COORDINATION; MOUSE; NEUROPATHOLOGY; NIEMANN PICK DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PURKINJE CELL; RAT; STRUCTURE ANALYSIS; ANIMAL; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; BETA-GLUCOSIDASE; GLUCOSYLCERAMIDES; MICE; MICE, KNOCKOUT; NIEMANN-PICK DISEASE, TYPE C; PROTEINS; PURKINJE CELLS;

EID: 84942894832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135889     Document Type: Article

References (43)

1. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun. 1965; 18: 221-5. PMID: 14282020
2. Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013; 70: 727-35. doi: 10. 1001/jamaneurol.2013.1925 PMID: 23588557
3. Hopfner F, Schulte EC, Mollenhauer B, Bereznai B, Knauf F, Lichtner P, et al. The role of SCARB2 as susceptibility factor in Parkinson's disease. Mov Disord. 2013; 28: 538-40. doi: 10.1002/mds.25349 PMID: 23408458
4. Van Weely S, Brandsma M, Strijland A, Tager JM, Aerts JM. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim Biophys Acta. 1993; 1181: 55-62. PMID: 8457606
5. Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, et al. Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem. 2007; 282: 1305-12. doi: 10.1074/jbc.M610544200 PMID: 17105727
6. Koerschen HG, Yildiz Y, Raju DN, Schonauer S, Boenigk W, Jansen V, et al. The non-lysosomal betaglucosidase GBA2 is a non-integral membrane-associated protein at the ER and Golgi. J Biol Chem. 2012; 288: 3381-93. doi: 10.1074/jbc.M112.414714 PMID: 23250757
7. Burke DG, Rahim AA, Waddington SN, Karlsson S, Enquist I, Bhatia K, et al. Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes. J Inherit Metab Dis. 2013; 36: 869-72. doi: 10.1007/s10545-012-9561-3 PMID: 23151684
8. Mistry PK, Liu J, Sun L, Chuang W- L, Yuen T, Yang R, et al. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci USA. 2014; 111: 4934-9. doi: 10.1073/pnas. 1400768111 PMID: 24639522
9. Yildiz Y, Hoffmann P, Vom Dahl S, Breiden B, Sandhoff R, Niederau C, et al. Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease. Orphanet J Rare Dis. 2013; 8: 151. doi: 10.1186/1750-1172-8-151 PMID: 24070122
10. Aerts JM, Hollak C, Boot R, Groener A. Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci. 2003; 358: 905-14. doi: 10.1098/ rstb.2003.1273 PMID: 12803924
11. Vanier MT. Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. Biochim Biophys Acta. 1983; 750: 178-84. PMID: 6824712
12. Pentchev PG, Gal AE, Booth AD, Omodeo-Sale F, Fouks J, Neumeyer BA, et al. A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase. Biochim Biophys Acta. 1980; 619: 669-79. PMID: 6257302
13. Salvioli R, Scarpa S, Ciaffoni F, Tatti M, Ramoni C, Vanier MT, et al. Glucosylceramidase mass and subcellular localization are modulated by cholesterol in Niemann-Pick disease type C. J Biol Chem. 2004; 279: 17674-80. doi: 10.1074/jbc.M313517200 PMID: 14757764
14. Sleat DE, Wiseman JA, El-Banna M, Price SM, Verot L, Shen MM, et al. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc Natl Acad Sci USA. 2004; 101: 5886-91. doi: 10.1073/pnas.0308456101 PMID: 15071184
15. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010; 5: 1-18. doi: 10.1186/1750- 1172-5-16
16. Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, Brown A, et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science. 1997; 277: 232-5. PMID: 9211850
17. Yildiz Y, Matern H, Thompson B, Allegood JC, Warren RL, Ramirez DMO, et al. Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J Clin Invest. 2006; 116: 2985-94. doi: 10.1172/JCI29224 PMID: 17080196
18. Van der Loos CM. Chromogens in Multiple Immunohistochemical Staining Used for Visual Assessment and Spectral Imaging: The Colorful Future. J Histotech. Maney PublishingSuite 1C, Joseph's Well, Hanover Walk, Leeds LS3 1AB, UK; 2010; 33: 31-40. doi: 10.1179/his.2010.33.1.31
19. Kallemeijn WW, Li K-Y, Witte MD, Marques ARA, Aten J, Scheij S, et al. Novel Activity-Based Probes for Broad-Spectrum Profiling of Retaining β-Exoglucosidases In Situ and In Vivo. Angew Chem Int Ed Engl. 2012; 51: 12529-12533. doi: 10.1002/anie.201207771 PMID: 23139194
20. Witte MD, Kallemeijn WW, Aten J, Li K- Y, Strijland A, Donker-Koopman WE, et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol. Nature Publishing Group; 2010; 6: 907-13. doi: 10.1038/nchembio.466
21. Apps R, Hawkes R. Cerebellar cortical organization: a one-map hypothesis. Nat Rev Neurosci. 2009; 10: 670-81. doi: 10.1038/nrn2698 PMID: 19693030
22. Van Der Giessen RS, Koekkoek SK, van Dorp S, De Gruijl JR, Cupido A, Khosrovani S, et al. Role of olivary electrical coupling in cerebellar motor learning. Neuron. 2008; 58: 599-612. doi: 10.1016/j. neuron.2008.03.016 PMID: 18498740
23. Vinueza Veloz MF, Buijsen RAM, Willemsen R, Cupido A, Bosman LWJ, Koekkoek SKE, et al. The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav. 2012; 11: 325-31. doi: 10.1111/j.1601-183X.2011.00763.x PMID: 22257369
24. Vinueza Veloz MF, Zhou K, Bosman LWJ, Potters J-W, Negrello M, Seepers RM, et al. Cerebellar control of gait and interlimb coordination. Brain Struct Funct. 2014;[Epub]. doi: 10.1007/s00429-014-0870- 1
25. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226: 497-509. PMID: 13428781
26. Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CEM, Aerts JM, et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta. 2008; 389: 109-13. doi: 10.1016/j.cca.2007.12.001 PMID: 18164265
27. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37: 911-7. PMID: 13671378
28. Groener JEM, Poorthuis BJHM, Kuiper S, Helmond MTJ, Hollak CEM, Aerts JMFG. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin Chem. 2007; 53: 742-7. doi: 10.1373/clinchem.2006.079012 PMID: 17332150
29. Dekker N, van Dussen L, Hollak CEM, Overkleeft H, Scheij S, Ghauharali K, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011; 118: e118-27. doi: 10.1182/blood-2011-05-352971 PMID: 21868580
30. De Zeeuw CI, Hoebeek FE, Bosman LWJ, Schonewille M, Witter L, Koekkoek SK. Spatiotemporal firing patterns in the cerebellum. Nat Rev Neurosci. Nature Publishing Group; 2011; 12: 327-44. doi: 10. 1038/nrn3011
31. Sarna JR, Larouche M, Marzban H, Sillitoe R V, Rancourt DE, Hawkes R. Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease. J Comp Neurol. 2003; 456: 279-91. doi: 10.1002/cne.10522 PMID: 12528192
32. Parra J, Klein AD, Castro J, Morales MG, Mosqueira M, Valencia I, et al. Npc1 deficiency in the C57BL/ 6J genetic background enhances Niemann-Pick disease type C spleen pathology. Biochem Biophys Res Commun. 2011; 413: 400-6. doi: 10.1016/j.bbrc.2011.08.096 PMID: 21910975
33. Overkleeft HS, Renkema GH, Neele J, Vianello P, Hung IO, Strijland A, et al. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem. 1998; 273: 26522-7. PMID: 9756888
34. Ashe KM, Bangari D, Li L, Cabrera-Salazar M a, Bercury SD, Nietupski JB, et al. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of sandhoff disease. PLoS One. 2011; 6: e21758. doi: 10.1371/journal.pone.0021758 PMID: 21738789
35. Sarkar S, Carroll B, Buganim Y, Maetzel D, Ng AHM, Cassady JP, et al. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease. Cell Rep. 2013; 5: 1302-15. doi: 10.1016/j. celrep.2013.10.042 PMID: 24290752
36. Elleder M. Glucosylceramide transfer from lysosomes-the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis. 2006; 29: 707-15. doi: 10.1007/s10545-006-0411-z PMID: 17080304
37. Sorli S-C, Colié S, Albinet V, Dubrac A, Touriol C, Guilbaud N, et al. The nonlysosomal β-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB J. 2012; 27: 498-98. doi: 10.1096/fj.12-215152
38. Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994; 269: 8362-5. PMID: 8132559
39. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebícek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000; 355: 1481-5. doi: 10.1016/S0140-6736(00)02161-9 PMID: 10801168
40. Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 2001; 11: 1283-7. PMID: 11525744
41. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007; 6: 765-72. doi: 10.1016/S1474-4422(07) 70194-1 PMID: 17689147
42. Wennekes T, van den Berg RJBHN, Donker W, van der Marel GA, Strijland A, Aerts JMFG, et al. Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J Org Chem. 2007; 72: 1088-97. doi: 10.1021/jo061280p PMID: 17243712
43. Nietupski JB, Pacheco JJ, Chuang W-L, Maratea K, Li L, Foley J, et al. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol Genet Metab. 2012; 105: 621-8. doi: 10.1016/j.ymgme.2012.01.020 PMID: 22366055